# US 2013/0296539 A1 · Magnetic resonance imaging agents for calcification

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0296539 A1
- Document ID: US20130296539A1
- Status: Published application
- Kind: A1
- Application number: 13/465,301
- Filed: 2012-05-07
- Published: 2013-11-07
- Earliest claimed: 2012-05-07
- Inventors: Kumar Ranjan Bhushan
- Web page: https://patentgrep.com/patent/US20130296539A1

## CPC

- C07F 5/003: {without C-Metal linkages}
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

The present invention discloses magnetic resonance compatible contrast agents for water-poor structures, such as bone and tissue calcification. In particular, the present invention discloses bisphosphonate-based magnetic resonance imaging contrast agents specific for hydroxyapatite, the calcium salt most commonly associated with malignant calcification.

## Claims

### Claim 1

A contrast agent represented in general formula [I], and pharmaceutically acceptable salts, hydrates and solvents thereof:
wherein
BP is a bisphosphonate;
is a linker; and
is a metal chelate selected independently from:

### Claim 2 (depends on 1)

The contrast agent of claim 1, wherein said bisphosphonate is independently selected from the group consisting of alendronate, etidronate, ibandronate, incadronate, neridronate, olpadronate, phosphonate, pamidronate, risedronate, tiludronate and zoledronate.

### Claim 3 (depends on 1)

The contrast agent of claim 1, wherein said linker is selected from the group consisting of amino acid, alkane, polyethylene glycol and polypropylene glycol.

### Claim 4 (depends on 1)

The contrast agent of claim 1, wherein M is selected from the group consisting of Y, In, Gd, Eu and lanthanide, wherein Gd is chelated for magnetic resonance imaging, Eu is chelated for CEST imaging and Y is chelated for hyperpolarized imaging.

### Claim 5

A contrast agent represented in general formula [II], and pharmaceutically acceptable salts, hydrates and solvents thereof:
wherein
BP is a bisphosphonate;
is a linker; and
M is Y, In, Gd, Eu, or a lanthanide.

### Claim 6 (depends on 5)

The contrast agent of claim 5, wherein said linker is selected from the group consisting of amino acid, alkane, polyethylene glycol and polypropylene glycol.

### Claim 7 (depends on 5)

The contrast agent of claim 5, wherein said bisphosphonate is independently selected from the group consisting of alendronate, etidronate, ibandronate, incadronate, neridronate, olpadronate, phosphonate, pamidronate, risedronate, tiludronate and zoledronate.

### Claim 8

A contrast agent having a formula selected from the group consisting of:
wherein
BP is a bisphosphonate;
is a linker; and
M is Y, In, Gd, Eu, or a lanthanide.

### Claim 9 (depends on 8)

The contrast agent of claim 8, wherein said linker is selected from the group consisting of amino acid, alkane, polyethylene glycol and polypropylene glycol.

### Claim 10 (depends on 8)

The contrast agent of claim 8, wherein said contrast agent is in a form of pharmaceutically acceptable salts, hydrates and solvents.

### Claim 11 (depends on 8)

The contrast agent of claim 8, wherein Gd is chelated for magnetic resonance imaging, Eu is chelated for CEST imaging and Y is chelated for hyperpolarized imaging.

### Claim 12

A method of making a contrast agent, said method comprising:
(a) providing an organic chelating ligand, wherein said organic chelating ligand selected from the group consisting of:
wherein
R is t-butyl ester, ester or hydrogen; and
R1 is
(b) reacting said organic chelating ligand with a linker, wherein said linker having a primary amine and a carboxylic moiety at opposing ends;
(c) treating said carboxylic moiety with oxalyl chloride under conditions capable of forming an acid chloride at said carboxylic moiety;
(d) reacting said acid chloride in one pot with trialkyl phosphite and dialkyl phosphite to form a alkylester protected bisphosphonate;
(e) deprotecting one or more carboxylic acid ester of said organic chelating ligand to yield one or more carboxylic acid functionality;
(f) chelating a metal ion to result in a metal chelate, wherein said linker separate said metal chelate and said alkylester protected bisphosphonate; and
(g) deprotecting one or more bisphosphonate ester of said alkylester protected bisphosphonate, wherein deprotection results in said contrast agent.

### Claim 13 (depends on 12)

The method of claim 12, wherein said linker is selected from the group consisting of amino acid, alkane, polyethylene glycol and polypropylene glycol.

### Claim 14 (depends on 12)

The method of claim 12, wherein said metal ion is selected from the group consisting of Y, In, Gd, Eu and lanthanide, wherein Gd is chelated for magnetic resonance imaging, Eu is chelated for CEST imaging and Y is chelated for hyperpolarized imaging.

### Claim 15

A method of making a contrast agent, said method comprising:
(a) providing an organic chelating ligand, wherein said organic chelating ligand selected from the group consisting of:
wherein
R is t-butyl ester, ester or hydrogen; and
R1 is
(b) reacting said organic chelating ligand with a linker, wherein said linker having a primary amine and a carboxylic moiety at opposing ends;
(c) deprotecting one or more carboxylic acid ester of said organic chelating ligand to yield one or more carboxylic acid functionality;
(d) chelating a metal ion to result in a metal chelate, wherein said linker on said metal chelate having said carboxylic moiety; and
(e) reacting an amino bisphosphonate with said carboxylic moiety of said metal chelate under a condition capable of forming amide bond to results in said contrast agent.

### Claim 16 (depends on 15)

The method of claim 15, wherein said linker is selected from the group consisting of amino acid, alkane, polyethylene glycol and polypropylene glycol.

### Claim 17 (depends on 15)

The method of claim 15, wherein said amino bisphosphonate is an amino alkylester protected bisphosphonate, wherein deprotection of one or more bisphosphonate ester results in said contrast agent.

### Claim 18 (depends on 15)

The method of claim 15, wherein said metal ion is selected from the group consisting of Y, In, Gd, Eu and lanthanide, wherein Gd is chelated for magnetic resonance imaging, Eu is chelated for CEST imaging and Y is chelated for hyperpolarized imaging.

### Claim 19

A method of making a contrast agent, said method comprising:
(a) providing an organic chelating ligand, wherein said organic chelating ligand selected from the group consisting of:
wherein
R is t-butyl ester, ester or hydrogen; and
R1 is
(b) reacting an amino bisphosphonate with said organic chelating ligand under a condition capable of forming amide bond between said amino bisphosphonate and said organic chelating ligand;
(c) deprotecting one or more carboxylic acid ester of said organic chelating ligand to yield one or more carboxylic acid functionality; and
(d) chelating a metal ion to said one or more carboxylic acid ester of said organic chelating ligand to result in said contrast agent.

### Claim 20 (depends on 19)

The method of claim 19, wherein a linker separates said organic chelating ligand and said amino bisphosphonate, wherein said amino bisphosphonate is independently selected from the group consisting of alendronate, neridronate, and pamidronate, wherein said linker is selected from the group consisting of amino acid, alkane, polyethylene glycol and polypropylene glycol.

### Claim 21 (depends on 19)

The method of claim 19, wherein said metal ion is selected from the group consisting of Y, In, Gd, Eu and lanthanide, wherein Gd is chelated for magnetic resonance imaging, Eu is chelated for CEST imaging and Y is chelated for hyperpolarized imaging.
